Skip Navigation



Schizophrenia Bulletin Advance Access published online on August 17, 2005
Schizophrenia Bulletin, doi:10.1093/schbul/sbi046
This Article
Right arrow Full Text (Rapid PDF)
Right arrow All Versions of this Article:
31/4/810    most recent
sbi046v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Carter, C. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Carter, C. S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2005. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center. All rights reserved. For permissions, please email: journals.permissions@oupjournals.org.

Article

Applying New Approaches From Cognitive Neuroscience to Enhance Drug Development for the Treatment of Impaired Cognition in Schizophrenia

Cameron S. Carter 1*
1 Department of Psychiatry, University of California at Davis, Imaging Research Center, 4701 X Street Sacramento, CA 95817

* To whom correspondence should be addressed.
Cameron S. Carter, E-mail: cameron.carter{at}ucdmc.ucdavis.edu


  Abstract

New approaches to the measurement of cognition in schizophrenia include the use of tasks from experimental cognitive psychology to examine the integrity of specific cognitive systems and the application of these tasks in noninvasive neuroimaging (e.g., functional magnetic resonance imaging [fMRI]) studies that directly measure the effects of drugs on cognition-related brain activity. These approaches offer many advantages, including the isolation of specific cognitive systems that may be conserved across species; controlling for the confounding effects of generalized performance deficits such as poor motivation, sedation, and so on; and providing a direct translational bridge from studies using animal models of cognition to patient-based research using fMRI. These developments have the potential to transform the early human phases of drug development and streamline the decision making at this critical point in the process. As was the case for the Measurement and Treatment Research to Improve Cognition in Schizophrenia initiative, optimizing the application of cognitive neuroscience to new drug development will require a major commitment by multiple investigators to task development and a thorough psychometric evaluation of both behavioral and neuroimaging measures.

Keywords: Cognitive psychology; cognitive neuroscience; neuropsychology; schizophrenia; cognitive enhancement.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Schizophr BullHome page
D. Dickinson and P. D. Harvey
Systemic Hypotheses for Generalized Cognitive Deficits in Schizophrenia: A New Take on An Old Problem
Schizophr Bull, March 1, 2009; 35(2): 403 - 414.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. PsychiatryHome page
D. A. Lewis, R. Y. Cho, C. S. Carter, K. Eklund, S. Forster, M. A. Kelly, and D. Montrose
Subunit-Selective Modulation of GABA Type A Receptor Neurotransmission and Cognition in Schizophrenia
Am J Psychiatry, December 1, 2008; 165(12): 1585 - 1593.
[Abstract] [Full Text] [PDF]

Home page
 Schizophr BullHome page
D. Dickinson and J. M. Gold
Less Unique Variance Than Meets the Eye: Overlap Among Traditional Neuropsychological Dimensions in Schizophrenia
Schizophr Bull, May 1, 2008; 34(3): 423 - 434.
[Abstract] [Full Text] [PDF]

Home page
 Schizophr BullHome page
C. S. Carter and D. M. Barch
Cognitive Neuroscience-Based Approaches to Measuring and Improving Treatment Effects on Cognition in Schizophrenia: The CNTRICS Initiative
Schizophr Bull, September 1, 2007; 33(5): 1131 - 1137.
[Abstract] [Full Text] [PDF]

Home page
 Schizophr BullHome page
E. Stover, S. Marder, and W. Carpenter
Progress on NIMH Initiatives (Memorial Theme for Wayne Fenton, MD)
Schizophr Bull, September 1, 2007; 33(5): 1084 - 1085.
[Full Text] [PDF]

Home page
 Schizophr BullHome page
E. L. Stover, L. Brady, and S. R. Marder
New Paradigms for Treatment Development
Schizophr Bull, September 1, 2007; 33(5): 1093 - 1099.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. PsychiatryHome page
C. S. CARTER
Understanding the Glass Ceiling for Functional Outcome in Schizophrenia
Am J Psychiatry, March 1, 2006; 163(3): 356 - 358.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.